

**EDITORIAL*****Oncologie* Issue 1, 2022****Daniel Serin**

Sainte-Catherine, Institut du Cancer Avignon-Provence, Avignon, 84918, France

Received: 30 November 2021 Accepted: 24 March 2022

From the very beginning, we wished to make *Oncologie* a place of exchange open to all the actors in oncology, from the researchers and clinicians to the healthcare teams and paramedics. The opening of our magazine and columns to all of these professionals, from all of these points of view on cancer, can initially surprise our readers, but we think that the decompartmentalisation of our professions is a factor of mutual enrichment and will increase the quality of management of cancer patients.

*Oncologie* is the only bilingual journal published simultaneously in English and French. If English has become the language of international exchanges, we have kept a significant place for French-speaking authors more at ease in the language of Marie Curie than in that of Shakespeare.

This initiative is founded by the certainty that the use of French language “francophonie” remains important to promote the notoriety of our French-speaking colleagues who can make their experiences and scientific discoveries heard around the world.

We want to be exemplary in the way that we structure and build *Oncologie* with respect to ethics and scientific integrity, by following COPE guidelines and the international rules of ICMJE to eliminate all possible misconducts and plagiarism, refuse and eliminate papers already published in other languages.

In 2021, *Oncologie* published 4 issues and 46 papers. There will be 60 articles or more in 2022. We wish to express our warm thanks to the authors who chose *Oncologie*, and reviewers and readers who have contributed to the development of our publication in this launching year and the new version of *Oncologie*.

Faced with a multiplicity of hyper-specialized publications in increasingly narrow domains, our strategic vision to involve all the professionals concerned by cancer healthcare is attracting more actors who are no longer satisfied with the limited audience that other media proposes. Our open strategy finds its justification in the adherence of the oncology community to our strategic ambitions.

At this time, most of our publications have been centered on biology, biochemistry, immunology and the research of new molecules of herb derivatives are able to enter the arsenal of clinicians. Some publications by nurses or clinicians have succeeded in the peer review process, are very interesting for our readers involved in the cancer care pathway, and contribute to our strategic objectives of openness to all the actors in the oncological activity.

**What can we say today?**

We published 4 issues in 2021. These articles included in *Oncologie* originated from countries including France, Japan, Mexico, Korea, Pakistan, Turkey, and Vietnam. We are expecting more publications from other European countries and the Americas in 2022.

There is a noticeable imbalance between the number of publications in French and those published in English. Several structural factors can explain this, amongst others, the considerable disproportion between the number of researchers speaking English. We are continuing our efforts to encourage French-



speaking oncologists to join us. In the latest issue 1, 2022, you will read a new review paper in French from the well-known specialists of the field, titled “Hairy Cell Leukemia and HCL-Like Disorders: Diagnosis and Treatment”. Other review papers in English include “Technological Innovations in Thyroid Cancer Surgery”, “The Integrated Histopathologic and Molecular Approach to Adult-Type Diffuse Astrocytomas: Status of the Art, Based on the 2021 WHO Classification of Central Nervous System Tumors”, “Gene Editing in Non-Small Cell Lung Cancer: Current Application and Future Perspective”, etc. And other articles from different fields. We believe that you will enjoy these papers.

Our group of experts has expanded to face the great richness and diversity of the proposed articles and with this challenge we have chosen to broaden their numbers. If all our reviewers are familiar with the form that a publication must respect to be published, the diversity of the subject of research is so wide that it is very hard to appreciate the scientific content of all the papers sent to the journal. The journal will constitute a “team of reviewers” devoted to specific fields specialized for biochemical issues and for clinical localisations as breast cancer, GI tract cancer, GU, head and neck, lymphomas and malignant hematologic diseases.

### **What is the future for *Oncologie*?**

Our four strategies, openness, bilingualism, scientific integrity and reactivity will help guide us in the future. These principles, chosen at the very beginning of *Oncologie*, are our backbone. Many online publications are invading our laptops asking us to publish quickly with no consideration for quality and scientific integrity. The journal will never heed to this way of functioning so that we are sure to be chosen by honorable researchers, clinicians, nurses and paramedical staff who need share their knowledge and experiences with colleagues coming from other cultures. The competition is severe, but our quality and integrity will make a difference and lead to our success. We are certain to participate in this way and within the limits of our mission as a scientific media to improve the management and increase the cure rates of cancer patients worldwide.